All Stories

  1. Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15

    Article • PharmacoEconomics - Open, September 2023, Springer Science + Business Media

    Mr Nigel David Fleeman

  2. Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics - Open, April 2023, Springer Science + Business Media

    Mr Nigel David Fleeman

  3. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation

    Article • Health Technology Assessment, January 2020, National Institute for Health Research

    Dr Rui Duarte, Mr Nigel David Fleeman

  4. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

    Article • BMC Cancer, December 2019, Springer Science + Business Media

    Dr Rui Duarte, Mr Nigel David Fleeman

  5. Care delivery and self management strategies for adults with epilepsy

    Article • Cochrane Database of Systematic Reviews, February 2016, Wiley

    Mr Nigel David Fleeman

  6. Care delivery and self management strategies for children with epilepsy

    Article • Cochrane Database of Systematic Reviews, December 2015, Wiley

    Mr Nigel David Fleeman

  7. Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis

    Article • Behaviour Research and Therapy, October 2015, Elsevier

    Mr Nigel David Fleeman, Dr Cleo Protogerou

  8. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

    Article • Health Technology Assessment, October 2015, National Institute for Health Research

    Mr Nigel David Fleeman

  9. Economic evaluations of personalized medicine: existing challenges and current developments

    Article • Pharmacogenomics and Personalized Medicine, June 2015, Taylor & Francis

    Mr Nigel David Fleeman

  10. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective

    Article • PharmacoEconomics, April 2015, Springer Science + Business Media

    Mr Nigel David Fleeman

  11. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis

    Article • Health Technology Assessment, April 2015, National Institute for Health Research

    Mr Nigel David Fleeman

  12. Deferasirox for managing iron overload in people with myelodysplastic syndrome

    Article • Cochrane Database of Systematic Reviews, October 2014, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  13. Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer

    Article • PharmacoEconomics, August 2014, Springer Science + Business Media

    Mr Nigel David Fleeman

  14. Deferasirox for managing transfusional iron overload in people with sickle cell disease

    Article • Cochrane Database of Systematic Reviews, June 2014, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  15. Allopurinol for the treatment of chronic kidney disease: asystematic review

    Article • Health Technology Assessment, June 2014, National Institute for Health Research

    Mr Nigel David Fleeman

  16. Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifen

    Article • Personalized Medicine, August 2013, Future Medicine

    Mr Nigel David Fleeman

  17. Deferasirox for managing iron overload in people with thalassaemia

    Article • February 2012, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  18. Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE

    Article • PharmacoEconomics Italian Research Articles, July 2011, Springer Science + Business Media

    Mr Nigel David Fleeman

  19. Deferasirox for managing iron overload in people with myelodysplastic syndrome

    Article • November 2010, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  20. Deferasirox for managing transfusional iron overload in people with sickle cell disease

    Article • August 2010, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  21. Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Article • PharmacoEconomics, June 2010, Springer Science + Business Media

    Mr Nigel David Fleeman, Adrian Bagust

  22. Providing patients with information on pharmacogenetic testing

    Article • Nursing Standard, January 2009, RCNi

    Mr Nigel David Fleeman

  23. Deferasirox for managing transfusional iron overload in people with sickle cell disease

    Article • October 2008, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  24. Deferasirox for managing iron overload in people with thalassaemia

    Article • October 2008, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  25. Deferasirox for managing iron overload in patients with myelodysplastic syndrome

    Article • October 2008, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  26. So many filters, so little time: the development of a search filter appraisal checklist

    Article • Journal of the Medical Library Association JMLA, October 2008, Medical Library Association

    Mr Nigel David Fleeman, Ms Julie Glanville